NVS  Novartis Ag

Exchange

NYSE

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

228.8B

Vuru Grade

66.34/100

Current Price

$94.61
+0.04 (+0.04%)

Growth Price

$67.94
Overvalued by 28.19%

Stability Price

$24.72
Overvalued by 73.87%

Company Metrics

  • 21.73 P/E
  • 3.83 P/S
  • 3.21 P/B
  • 4.352 EPS
  • 13.46% Cash ROIC
  • 0.35 Cash Ratio
  • 2.719 / 2.88% Dividend
  • 1.35M Avg. Vol.
  • 2.42B Shares
  • 228.8B Market Cap.

Company Description

Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. Its Pharmaceuticals division offers prescription medicines in various therapeutic areas, including cardiovascular and metabolism; oncology; neuroscience and ophthalmics; respiratory; integrated hospital care; and other additional products. The company's Vaccines...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

GSK Shareholders In Favor Of Novartis (NVS) Deal
Bidness ETC - Dec 19, 2014
GlaxoSmithKline plc (ADR) (NYSE:GSK) announced that its shareholders voted in “overwhelming majority” in favor of the company's multi-billion swapping deal with Novartis AG (ADR) (NYSE:NVS) in the annual shareholder meeting held on December 18.
FDA Okays Novartis AG's (NVS) Signifor LAR To Treat Acromegaly
Bidness ETC - Dec 17, 2014
Novartis AG (ADR) (NYSE:NVS) announced Tuesday that its drug Signifor LAR has been approved by the US Food and Drug Administration (FDA) to treat acromegaly in patients on whom prior treatments have not worked or for whom surgery is not an option.
Novartis (NVS) Beats Johnson & Johnson (JNJ) In Clinical Trial
Bidness ETC - Dec 15, 2014
Novartis AG's (ADR) (NYSE:NVS) plaque psoriasis treatment Cosentyx continued to produce impressive results in its clinical trial.
Here's Why Novartis AG (NVS) Stock Could Fall Today
Bidness ETC - Dec 1, 2014
Novartis AG (ADR) (NYSE:NVS) announced early Monday morning that its drug Gilenya failed to meet its primary endpoint in a Phase III study, called INFORMS, designed to measure the efficacy of the drug in treating primary-progressive multiple sclerosis ...
Novartis (NVS) Fails To Sidestep Patent Infringement
Bidness ETC - Dec 6, 2014
Novartis AG (ADR) (NYSE:NVS) has failed to invalidate Amgen Inc.'s (NASDAQ:AMGN) patents for the autoimmune drug Enbrel, as the US patent court decided to dismiss the suit filed by the former's generic division, Sandoz Inc. The company sought a ruling ...
Novartis AG ADR (NVS): New Analyst Report from Zacks Equity Research ...
NASDAQ - Jul 25, 2014
Novartis reported third-quarter 2014 earnings per share of $1.33, up 48% from the year-ago period. Core earnings per share came in at $1.37, up 10% from the year-ago period and beat the Zacks Consensus Estimate of $1.29.
Novartis AG (ADR) Boosts its Cancer Immunotherapy Presence
Motley Fool - Feb 18, 2014
Despite outstanding performance over the past year from biotech and pharma, you wouldn't be alone if you think they have more room to grow.
Novartis (NVS) to acquire start-up CoStim Pharmaceuticals in immunotherapy ... - Stockhouse
Novartis' (NVS) Signifor Wins EU Approval For Rare Hormonal Disorder
Bidness ETC - Nov 24, 2014
Novartis AG (ADR) (NYSE:NVS) announced before US markets opened for trading Monday that the European Commission has approved its drug Signifor for the treatment of a rare hormonal disorder that is believed to affect about 1-2 in every 10,000 ...
Novartis Posts Strong Third-Quarter Results; Cost-Cutting Efforts Pay Off
Bidness ETC - Oct 28, 2014
Novartis AG (ADR) (NVS) posted upbeat financial and operational results for the third quarter of its fiscal year (3QFY14) today before markets opened.
Novartis (NVS) Beats on Q3 Earnings, Revenues; Keeps View - Analyst Blog - Nasdaq
Healthcare Stocks To Watch Today: Actavis (ACT), Novartis (NVS), Merck (MRK ...
Bidness ETC - Dec 12, 2014
The decline came on a downgrade by Credit Suisse Group AG (ADR) (NYSE:CS) and due to other sell-side analysts giving the stock an overall Hold rating.